Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083486 · ClinicalTrials.gov registry record · Phase 3
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00083486: Clinical Trial Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00083486 is a Phase 3 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083486, a Phase 3 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.
Interventions
- DRUG epoetin alfa
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-02 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Why NCT00083486 stopped before completion
NCT00083486 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which epoetin alfa is the first listed.
NCT00083486 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00083486 about?
NCT00083486 is a clinical study titled "Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy". The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemo...
What is the current status of trial NCT00083486?
This trial is currently terminated. It is a Phase 3 study. The study started on 2004-02. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00083486?
The interventions under investigation include: epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00083486?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia